| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Bo Tao, Yuan Xiao, Hengyi Cao, Wenjing Zhang, Chengmin Yang, Rebekka Lencer, Qiyong Gong, Su Lu. Characteristics of the corpus callosum in chronic schizophrenia treated with clozapine or risperidone and those never-treated. BMC psychiatry. vol 21. issue 1. 2021-12-03. PMID:34715831. |
characteristics of the corpus callosum in chronic schizophrenia treated with clozapine or risperidone and those never-treated. |
2021-12-03 |
2023-08-13 |
Not clear |
| Chen Lin, Ke Chen, Jianjin Yu, Wei Feng, Weihong Fu, Fude Yang, Xiangyang Zhang, Dachun Che. Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients. BMC psychiatry. vol 21. issue 1. 2021-12-03. PMID:34763685. |
relationship between tnf-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients. |
2021-12-03 |
2023-08-13 |
Not clear |
| Chunyan Luo, Rebekka Lencer, Na Hu, Yuan Xiao, Wenjing Zhang, Siyi Li, Su Lui, Qiyong Gon. Characteristics of White Matter Structural Networks in Chronic Schizophrenia Treated With Clozapine or Risperidone and Those Never Treated. The international journal of neuropsychopharmacology. vol 23. issue 12. 2021-11-23. PMID:32808036. |
characteristics of white matter structural networks in chronic schizophrenia treated with clozapine or risperidone and those never treated. |
2021-11-23 |
2023-08-13 |
Not clear |
| Chunyan Luo, Rebekka Lencer, Na Hu, Yuan Xiao, Wenjing Zhang, Siyi Li, Su Lui, Qiyong Gon. Characteristics of White Matter Structural Networks in Chronic Schizophrenia Treated With Clozapine or Risperidone and Those Never Treated. The international journal of neuropsychopharmacology. vol 23. issue 12. 2021-11-23. PMID:32808036. |
this study sought to explore the characteristics of white matter structural networks in chronic never-treated schizophrenia and those treated with clozapine or risperidone, and its potential association with cognitive function. |
2021-11-23 |
2023-08-13 |
Not clear |
| Anne Le Moigne, John Csernansky, Robert A Leadbetter, Anne C Andorn, James A Graham, Amy T Heath, David P Walling, John W Newcomer, Stephen R Marde. PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly Extended-Release Risperidone) in Schizophrenia Patients. The Journal of clinical psychiatry. vol 82. issue 5. 2021-11-19. PMID:34551218. |
panss individual item and marder dimension analyses from a pivotal trial of rbp-7000 (monthly extended-release risperidone) in schizophrenia patients. |
2021-11-19 |
2023-08-13 |
Not clear |
| Haixia Liu, Hua Liu, Shuling Jiang, Lei Su, Yi Lu, Zhenli Chen, Xiaojing Li, Xirong Li, Xuemei Wang, Meihong Xiu, Xiangyang Zhan. Sex-specific association between antioxidant defense system and therapeutic response to risperidone in schizophrenia: a prospective longitudinal study. Current neuropharmacology. 2021-11-12. PMID:34766896. |
sex-specific association between antioxidant defense system and therapeutic response to risperidone in schizophrenia: a prospective longitudinal study. |
2021-11-12 |
2023-08-13 |
cat |
| Haixia Liu, Hua Liu, Shuling Jiang, Lei Su, Yi Lu, Zhenli Chen, Xiaojing Li, Xirong Li, Xuemei Wang, Meihong Xiu, Xiangyang Zhan. Sex-specific association between antioxidant defense system and therapeutic response to risperidone in schizophrenia: a prospective longitudinal study. Current neuropharmacology. 2021-11-12. PMID:34766896. |
these results indicate that after treatment with risperidone, changes in gpx activity were associated with treatment response, suggesting that changes in gpx may be a predictor of response to risperidone treatment in female patients with anfe schizophrenia. |
2021-11-12 |
2023-08-13 |
cat |
| Wonsuk Shin, Dong Hyeon Lee, Min-Kyoung Kim, Sang-Hyuk Lee, Doo-Yeoun Cho, Minji Ban. Clinical effectiveness of early treatment with paliperidone palmitate in schizophrenia: A retrospective real-world study in South Korea. Early intervention in psychiatry. vol 15. issue 6. 2021-11-08. PMID:33445224. |
this study aimed to ascertain the comparative real-world effectiveness between the early and late administration of pp and oral formulations of risperidone and paliperidone (orps) in patients experiencing a first episode or relapse of schizophrenia. |
2021-11-08 |
2023-08-13 |
Not clear |
| Shira Weizman, Assaf Shelef, Esther Bloemhof Bris, Rafael Stryje. A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or Risperidone in Overweight Individuals With Schizophrenia. Journal of clinical psychopharmacology. vol 41. issue 6. 2021-11-04. PMID:34735098. |
a double-blind, placebo-controlled trial of bupropion add-on to olanzapine or risperidone in overweight individuals with schizophrenia. |
2021-11-04 |
2023-08-13 |
Not clear |
| Hidenobu Suzuki, Hiroyuki Hibin. Comparison of treatment retention between risperidone long-acting injection, paliperidone palmitate, and aripiprazole once-monthly in elderly patients with schizophrenia. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society. 2021-11-03. PMID:34729877. |
comparison of treatment retention between risperidone long-acting injection, paliperidone palmitate, and aripiprazole once-monthly in elderly patients with schizophrenia. |
2021-11-03 |
2023-08-13 |
Not clear |
| Xi Rong Li, Mei Hong Xiu, Xiao Ni Guan, Yue Chan Wang, Jun Wang, Edison Leung, Xiang Yang Zhan. Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. vol 18. issue 2. 2021-11-02. PMID:33791970. |
altered antioxidant defenses in drug-naive first episode patients with schizophrenia are associated with poor treatment response to risperidone: 12-week results from a prospective longitudinal study. |
2021-11-02 |
2023-08-13 |
cat |
| Qijing Bo, Xiaomeng Xing, Tian Li, Zhen Mao, Fuchun Zhou, Chuanyue Wan. Menstrual Dysfunction in Women With Schizophrenia During Risperidone Maintenance Treatment. Journal of clinical psychopharmacology. vol 41. issue 2. 2021-10-26. PMID:33538534. |
menstrual dysfunction in women with schizophrenia during risperidone maintenance treatment. |
2021-10-26 |
2023-08-13 |
Not clear |
| Qijing Bo, Xiaomeng Xing, Tian Li, Zhen Mao, Fuchun Zhou, Chuanyue Wan. Menstrual Dysfunction in Women With Schizophrenia During Risperidone Maintenance Treatment. Journal of clinical psychopharmacology. vol 41. issue 2. 2021-10-26. PMID:33538534. |
this study evaluated menstrual dysfunction in women with schizophrenia given maintenance risperidone, and investigated the association between menstrual dysfunction and the duration and dose of risperidone and clinical symptoms. |
2021-10-26 |
2023-08-13 |
Not clear |
| A S Ozornin, N V Govorin, A V Sakharov, P P Tereshko. [Changes in adipokines in the blood of patients with the first episode of schizophrenia during treatment with haloperidol and risperidone]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 121. issue 9. 2021-10-26. PMID:34693690. |
[changes in adipokines in the blood of patients with the first episode of schizophrenia during treatment with haloperidol and risperidone]. |
2021-10-26 |
2023-08-13 |
Not clear |
| A S Ozornin, N V Govorin, A V Sakharov, P P Tereshko. [Changes in adipokines in the blood of patients with the first episode of schizophrenia during treatment with haloperidol and risperidone]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 121. issue 9. 2021-10-26. PMID:34693690. |
to study plasma adipokines (adiponectin, leptin, adipsin) in patients with the first episode of schizophrenia treated with haloperidol and risperidone. |
2021-10-26 |
2023-08-13 |
Not clear |
| Hiroyuki Uchida, Takefumi Suzuki, Ariel Graff-Guerrero, Benoit H Mulsant, Bruce G Pollock, Tamara Arenovich, Tarek K Rajji, David C Mam. Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients With Schizophrenia: A Pilot PET Study. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2021-10-21. PMID:23117199. |
participants:: subjects with schizophrenia age 50 years or more who were clinically stable and previously maintained on oral risperidone for more than 6 months. |
2021-10-21 |
2023-08-12 |
human |
| Heidi J Wehring, Sheryl Thedford, Maju Koola, Deanna L Kell. Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection. Journal of central nervous system disease. vol 2011. issue 3. 2021-10-21. PMID:23293546. |
olanzapine long acting injection has joined risperidone and paliperidone as the second generation long acting antipsychotic injection options for treatment of patients with schizophrenia. |
2021-10-21 |
2023-08-12 |
Not clear |
| P N Suresh Kumar, M K Radhika, Rohith Suresh, N A Uvai. Comparative Study of Sexual Side Effects in Female Patients With Schizophrenia Receiving Risperidone or Olanzapine. The primary care companion for CNS disorders. vol 23. issue 4. 2021-10-15. PMID:34297487. |
comparative study of sexual side effects in female patients with schizophrenia receiving risperidone or olanzapine. |
2021-10-15 |
2023-08-13 |
Not clear |
| Alexander Hodkinson, Carl Heneghan, Kamal R Mahtani, Evangelos Kontopantelis, Maria Panagiot. Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports. BMC medicine. vol 19. issue 1. 2021-10-15. PMID:34429113. |
benefits and harms of risperidone and paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports. |
2021-10-15 |
2023-08-13 |
human |
| Alexander Hodkinson, Carl Heneghan, Kamal R Mahtani, Evangelos Kontopantelis, Maria Panagiot. Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: a meta-analysis involving individual participant data and clinical study reports. BMC medicine. vol 19. issue 1. 2021-10-15. PMID:34429113. |
as existing evidence on both antipsychotics are solely based on aggregate data, we aimed to assess the benefits and harms of risperidone and paliperidone in the treatment of patients with schizophrenia or bipolar disorder, using individual participant data (ipd), clinical study reports (csrs) and publicly available sources (journal publications and trial registries). |
2021-10-15 |
2023-08-13 |
human |